Skip to main content
Login
Contact
Subscribe
Search form
Search
The Borger News-Herald
Home
Forms
News
Sports
Obituaries
Classifieds
Place an Ad
Classified Display Ads
Service Directory
Photos
Videos
Games
Entertainment
Calendar
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
Dow Jones Industrial Average
Nasdaq Composite
Standard & Poors 500
New York Composite
Gold
Crude Oil
Markets
Stocks
Funds
Tools
Overview
News
Currencies
International
Treasuries
News releases from Akari Therapeutics Plc
< Previous
1
2
Next >
Akari Therapeutics to Participate in Two January Virtual Investor Conferences
January 06, 2021
Tickers
AKTX
From
GlobeNewswire News Releases
Akari Therapeutics Reports Third Quarter 2020 Financial Results and Highlights Recent Clinical Progress
December 11, 2020
Tickers
AKTX
From
GlobeNewswire News Releases
Akari Therapeutics Announces New Clinical Data that Show Long-Term Self-Administered Nomacopan is Well-Tolerated and Substantially Reduces Transfusion Dependence in Patients with Paroxysmal Nocturnal
December 11, 2020
Tickers
AKTX
From
GlobeNewswire News Releases
Akari Therapeutics Announces Publication in American Journal of Pathology Highlighting Potential of Nomacopan in Treatment of Uveitis and Retinal Disease
December 03, 2020
Tickers
AKTX
From
GlobeNewswire News Releases
Akari Therapeutics to Present Phase II Data from Bullous Pemphigoid Trial at European Academy of Dermatology and Venereology (EADV) Virtual Congress October 29
October 27, 2020
Tickers
AKTX
From
GlobeNewswire News Releases
Akari Therapeutics Announces Further Clinical Trial Progress Using Nomacopan to Treat COVID-19 Pneumonia
October 06, 2020
Tickers
AKTX
From
GlobeNewswire News Releases
Akari Therapeutics Announces Successful Scientific Advice Meeting with the European Medicines Agency (EMA) Establishing a Clear Path in Both U.S. and Europe for a Pivotal Phase III Study of Nomacopan
October 01, 2020
Tickers
AKTX
From
GlobeNewswire News Releases
Akari Therapeutics to Present Its Phase III Plans at the International Pemphigus & Pemphigoid Foundation (IPPF) Patient Education Conference
September 29, 2020
Tickers
AKTX
From
GlobeNewswire News Releases
Akari Therapeutics to Participate in Two September Virtual Investor Conferences
September 10, 2020
Tickers
AKTX
From
GlobeNewswire News Releases
Akari Therapeutics Reports Second Quarter 2020 Financial Results and Highlights Recent Clinical Progress
September 01, 2020
Tickers
AKTX
From
GlobeNewswire News Releases
Akari Therapeutics Announces International Clinical Development Program of Nomacopan for the Potential Treatment of COVID-19 Pneumonia
August 31, 2020
Tickers
AKTX
From
GlobeNewswire News Releases
Akari Therapeutics Announces Successful End-of-Phase II Meeting With FDA to Initiate Pivotal Phase III Study for Treatment of Bullous Pemphigoid With Nomacopan
August 12, 2020
Tickers
AKTX
From
GlobeNewswire News Releases
Akari Therapeutics Enters into a Securities Purchase Agreement for up to $30 Million with Aspire Capital Fund, LLC
July 01, 2020
Tickers
AKTX
From
GlobeNewswire News Releases
Akari Therapeutics Announces Appointment of Chief Financial Officer
July 01, 2020
Tickers
AKTX
From
GlobeNewswire News Releases
Akari Therapeutics Reports First Quarter 2020 Financial Results and Highlights Recent Clinical Progress
May 29, 2020
Tickers
AKTX
From
GlobeNewswire News Releases
Akari Therapeutics Receives Positive EMA Opinion on Orphan Designation for Nomacopan for Bullous Pemphigoid
May 21, 2020
Tickers
AKTX
From
GlobeNewswire News Releases
Akari Therapeutics to Participate in STRH Life Sciences Virtual Meeting Series
May 04, 2020
Tickers
AKTX
From
GlobeNewswire News Releases
Akari Therapeutics Announces Positive Topline Results from Fully Recruited Phase II Study of Nomacopan in Bullous Pemphigoid Patients
May 01, 2020
Tickers
AKTX
From
GlobeNewswire News Releases
Akari Therapeutics Reports Fourth Quarter and Full Year 2019 Financial Results and Business Highlights
March 31, 2020
Tickers
AKTX
From
GlobeNewswire News Releases
Akari Therapeutics, Plc Announces Closing of $9.5 Million Private Placement
March 04, 2020
Tickers
AKTX
From
GlobeNewswire News Releases
Akari Therapeutics, Plc Announces Private Placement
February 20, 2020
Tickers
AKTX
From
GlobeNewswire News Releases
Akari Therapeutics Announces Preclinical Ophthalmic Data Showing Nomacopan Reduces Both Vascular Endothelial Growth Factor (VEGF) and Retinal Inflammation Supporting Nomacopan as a Potential Treatment
January 27, 2020
Tickers
AKTX
From
GlobeNewswire News Releases
Akari Therapeutics Announces Positive Interim Data from Phase III Paroxysmal Nocturnal Hemoglobinuria (PNH) Study
January 10, 2020
All patients treated with nomacopan have achieved the primary endpoint of transfusion independence
Tickers
AKTX
From
GlobeNewswire News Releases
Akari Therapeutics Announces Initiation of Pivotal Phase III Trial of Nomacopan in Pediatric Hematopoietic Stem Cell Transplant-Related Thrombotic Microangiopathy (HSCT-TMA) Following the Opening of i
December 23, 2019
Tickers
AKTX
From
GlobeNewswire News Releases
Akari Therapeutics Announces Pivotal Phase III Trial Design of Nomacopan in Pediatric Hematopoietic Stem Cell Transplant-Related Thrombotic Microangiopathy (HSCT-TMA), Following FDA Meeting
December 02, 2019
Tickers
AKTX
From
GlobeNewswire News Releases
Akari Therapeutics Reports Third Quarter 2019 Financial Results And Highlights Recent Clinical Progress
November 04, 2019
Tickers
AKTX
From
GlobeNewswire News Releases
Akari Therapeutics Announces New Data from Atopic Keratoconjunctivitis (AKC) Patients Supporting the Potentially Beneficial Role of Nomacopan as an Inhibitor of both C5 and LTB4 in the Ongoing Phase I
October 14, 2019
Tickers
AKTX
From
GlobeNewswire News Releases
Akari Therapeutics Announces Positive Phase II Clinical Data in Orphan Blistering Skin Disease Bullous Pemphigoid at the 28th EADV Congress
October 10, 2019
Tickers
AKTX
From
GlobeNewswire News Releases
Akari Therapeutics to Participate in Ladenburg Thalmann Healthcare Conference
September 18, 2019
Tickers
AKTX
From
GlobeNewswire News Releases
Akari Therapeutics’ Nomacopan Granted U.S. Orphan Drug Designation for Bullous Pemphigoid
September 13, 2019
Tickers
AKTX
From
GlobeNewswire News Releases
< Previous
1
2
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.
